109 related articles for article (PubMed ID: 20651367)
1. Biodistribution of two octreotate analogs radiolabeled with indium and yttrium in rats.
Laznickova A; Laznicek M; Trejtnar F; Maecke HR; Eisenwiener KP; Reubi JC
Anticancer Res; 2010 Jun; 30(6):2177-84. PubMed ID: 20651367
[TBL] [Abstract][Full Text] [Related]
2. Octreotide and octreotate derivatives radiolabeled with yttrium: pharmacokinetics in rats.
Laznicek M; Laznickova A; Mäcke HR; Eisenwiener K; Reubi JC; Wenger S
Cancer Biother Radiopharm; 2002 Oct; 17(5):527-33. PubMed ID: 12470422
[TBL] [Abstract][Full Text] [Related]
3. Biodistribution and elimination characteristics of two 111In-labeled CCK-2/gastrin receptor-specific peptides in rats.
Trejtnar F; Laznicek M; Laznickova A; Kopecky M; Petrik M; Béhé M; Schmidt J; Maecke H; Maina T; Nock B
Anticancer Res; 2007; 27(2):907-12. PubMed ID: 17465219
[TBL] [Abstract][Full Text] [Related]
4. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.
Konijnenberg MW; Bijster M; Krenning EP; De Jong M
J Nucl Med; 2004 Jul; 45(7):1260-9. PubMed ID: 15235075
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
Storch D; Béhé M; Walter MA; Chen J; Powell P; Mikolajczak R; Mäcke HR
J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541
[TBL] [Abstract][Full Text] [Related]
6. In vitro comparison of renal handling and uptake of two somatostatin receptor-specific peptides labeled with indium-111.
Trejtnar F; Novy Z; Petrik M; Laznickova A; Melicharova L; Vankova M; Laznicek M
Ann Nucl Med; 2008 Dec; 22(10):859-67. PubMed ID: 19142704
[TBL] [Abstract][Full Text] [Related]
7. Different radioactivity uptake between somatostatin analogues labelled with ¹¹¹In and ⁹⁰/⁸⁸Y in rat kidney.
Laznicek M; Laznickova A
Anticancer Res; 2012 Mar; 32(3):815-22. PubMed ID: 22399599
[TBL] [Abstract][Full Text] [Related]
8. Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size.
de Jong M; Breeman WA; Bernard BF; Bakker WH; Visser TJ; Kooij PP; van Gameren A; Krenning EP
J Nucl Med; 2001 Dec; 42(12):1841-6. PubMed ID: 11752083
[TBL] [Abstract][Full Text] [Related]
9. Distribution and elimination characteristics of 111In-DTPA-D-phe1-octreotide and 111In-DTPA-L-phe1-octreotide in rats.
Laznickova A; Laznicek M; Trejtnar F; Melicharova L; Suzuki KH; Akizawa H; Arano Y; Yokoyama A
Eur J Drug Metab Pharmacokinet; 2002; 27(1):37-43. PubMed ID: 11996325
[TBL] [Abstract][Full Text] [Related]
10. Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs.
Hofland LJ; Lamberts SW; van Hagen PM; Reubi JC; Schaeffer J; Waaijers M; van Koetsveld PM; Srinivasan A; Krenning EP; Breeman WA
J Nucl Med; 2003 Aug; 44(8):1315-21. PubMed ID: 12902423
[TBL] [Abstract][Full Text] [Related]
11. Comparison of 111In-DOTA-NOC and 111I-DOTA-TATE distribution in the target and dose-limiting tissues: conflicting results in vitro and in vivo.
Cihlo J; Melicharová L; Petrik M; Laznickova A; Laznicek M
Anticancer Res; 2008; 28(4B):2189-95. PubMed ID: 18751394
[TBL] [Abstract][Full Text] [Related]
12. Preliminary PET/CT Imaging with Somatostatin Analogs [
Satpati D; Shinto A; Kamaleshwaran KK; Sarma HD; Dash A
Mol Imaging Biol; 2017 Dec; 19(6):878-884. PubMed ID: 28349291
[TBL] [Abstract][Full Text] [Related]
13. Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide.
Barone R; Walrand S; Konijnenberg M; Valkema R; Kvols LK; Krenning EP; Pauwels S; Jamar F
Nucl Med Commun; 2008 Mar; 29(3):283-90. PubMed ID: 18349800
[TBL] [Abstract][Full Text] [Related]
14. D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake.
Bernard BF; Krenning EP; Breeman WA; Rolleman EJ; Bakker WH; Visser TJ; Mäcke H; de Jong M
J Nucl Med; 1997 Dec; 38(12):1929-33. PubMed ID: 9430472
[TBL] [Abstract][Full Text] [Related]
15. Complexation and biodistribution study of 111In and 90Y complexes of bifunctional phosphinic acid analogs of H4dota.
Försterová M; Petrík M; Láznicková A; Láznícek M; Hermann P; Lukes I; Melichar F
Appl Radiat Isot; 2009 Jan; 67(1):21-9. PubMed ID: 18951809
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the in vivo biodistribution of indium-111 and yttrium-88 labeled dendrimer-1B4M-DTPA and its conjugation with anti-Tac monoclonal antibody.
Kobayashi H; Wu C; Kim MK; Paik CH; Carrasquillo JA; Brechbiel MW
Bioconjug Chem; 1999; 10(1):103-11. PubMed ID: 9893971
[TBL] [Abstract][Full Text] [Related]
17. Treatment of patients who have endocrine gastroenteropancreatic tumors with radiolabeled somatostatin analogues.
Kwekkeboom DJ; Teunissen JJ; Kam BL; Valkema R; de Herder WW; Krenning EP
Hematol Oncol Clin North Am; 2007 Jun; 21(3):561-73; x. PubMed ID: 17548040
[TBL] [Abstract][Full Text] [Related]
18. Hepatobiliary handling of iodine-125-Tyr3-octreotide and indium-111-DTPA-D-Phe1-octreotide by isolated perfused rat liver.
de Jong M; Bakker WH; Breeman WA; van der Pluijm ME; Kooij PP; Visser TJ; Docter R; Krenning EP
J Nucl Med; 1993 Nov; 34(11):2025-30. PubMed ID: 8229254
[TBL] [Abstract][Full Text] [Related]
19. Renal metabolism of 111In-DTPA-D-Phe1-octreotide in vivo.
Akizawa H; Arano Y; Uezono T; Ono M; Fujioka Y; Uehara T; Yokoyama A; Akaji K; Kiso Y; Koizumi M; Saji H
Bioconjug Chem; 1998; 9(6):662-70. PubMed ID: 9815158
[TBL] [Abstract][Full Text] [Related]
20. Comparative dosimetry of copper-64 and yttrium-90-labeled somatostatin analogs in a tumor-bearing rat model.
Lewis JS; Laforest R; Lewis MR; Anderson CJ
Cancer Biother Radiopharm; 2000 Dec; 15(6):593-604. PubMed ID: 11190491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
